Clinical Trial of Therapeutic Effect of Valproic Acid in Retinitis Pigmentosa

Not Applicable

Completed

• Conditions: Retinitis Pigmentosa

• Registration Number: JPRN-jRCT1091220053
• Lead Sponsor: Yasuhiko Hirami

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2010-11-22
• Study Completion: 2013-12-28
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

Patients with Retinitis Pigmentosa with decreased visual acuity less than 0.7 and 0.1 or better in decimal visual acuity, and visual field less than 10 degrees by I-4 in Goldmann kinetic perimetry

Exclusion Criteria

1) Patients with retinal degeneration secondary to ocular infection or inflammation
2) Patients with ocular disease other than Retinitis Pigmentosa
3) Patients with pregnancy or breast-feeding
4) Patients with abnormality in liver function or urea cycle
5) Patients with any drug allergy
6) Patients with bipolar disorder and suicide attempt
7) Patients using following drugs; carbapenem antibiotic, barbiturate, phenytoin, carbamazepine, ethosuximide, amitoripuchin, norutoripuchin, kuropazamu, lamotrigine, salicylic acid, benzodiazepines, warfarin, erythromycin, cimetidine, clonazepam
8) any other case that research physicians decided to be inappropriate for the study

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Change in best corrected visual acuity